Emerging innovations in theranostics for pancreatic neuroendocrine tumors.

NPJ Precis Oncol · 2025 · PMC12089376 · PMID 40389624

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

This trial also included a subgroup analysis focused specifically on pNET patients, which demonstrated a favorable trend for disease control in those receiving lanreotide (HR = 0.58; 95% CI, 0.32–1.04) 43 .

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.